Expression of excision repair cross-complementation group 1 and class III β-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer

Mountain, 1997, Revisions in the international system for staging lung cancer, Chest, 111, 1719, 10.1378/chest.111.6.1710 van Rens, 2000, Prognostic assessment of 2361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA, Chest, 117, 374, 10.1378/chest.117.2.374 2004, Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer, N Engl J Med, 350, 351, 10.1056/NEJMoa031644 Winton, 2005, Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer, N Engl J Med, 352, 2589, 10.1056/NEJMoa043623 Douillard, 2006, Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial, Lancet Oncol, 7, 719, 10.1016/S1470-2045(06)70804-X Strauss GM, Herndon J, Maddaus A, Johnstone W, Johnson A, Watson M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2004;22:Suppl. 14:A7019 [abstract]. Wang, 2005, Cellular processing of platinum anticancer drugs, Nature Rev Drug Disc, 4, 307, 10.1038/nrd1691 Altaha, 2004, Excision repair cross complementing-group 1: gene expression and platinum resistance, Int J Mol Med, 14, 959 Lord, 2002, Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer, Clin Cancer Res, 8, 2286 Metzger, 1998, ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy, J Clin Oncol, 16, 309, 10.1200/JCO.1998.16.1.309 Burkhart, 2001, The role of β-tubulin isotypes in resistance to antimitotic drugs, Biochem Biophys Acta, 1471, 1 Katsetos, 2003, Class III β-tubulin isotype: a key cytoskeleral protein at the crossroads of developmental neurobiology and tumor neuropathology, J Child Neurol, 18, 851, 10.1177/088307380301801205 Lu, 1993, Removal lf β III isotype enhances taxol induced microtubule assembly, Cell Struct Funct, 18, 173, 10.1247/csf.18.173 Kamath, 2005, β III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability, J Biol Chem, 280, 12902, 10.1074/jbc.M414477200 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Pao, 2004, EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc Natl Acad Sci USA, 101, 10.1073/pnas.0405220101 Al Haddad, 1999, Psoriasin (S100A7) expression and invasive breast cancer, Am J Pathol, 155, 2057, 10.1016/S0002-9440(10)65524-1 Handara-Luca, 2003, Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation, Am J Pathol, 163, 957, 10.1016/S0002-9440(10)63455-4 Seve, 2005, Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy, Clin Cancer Res, 11, 5481, 10.1158/1078-0432.CCR-05-0285 Endo, 2005, Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay, Lung Cancer, 50, 375, 10.1016/j.lungcan.2005.08.009 Reed, 1993, Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies, Cancer Res, 53, 3694 Olaussen, 2006, DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy, N Engl J Med, 355, 983, 10.1056/NEJMoa060570 Azuma, 2007, Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy, Cancer Sci, 98, 1336, 10.1111/j.1349-7006.2007.00557.x Li, 2000, Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells, Anticancer Res, 20, 645 Lee, 1993, Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3, Carcinogenesis, 14, 2177, 10.1093/carcin/14.10.2177 Rosell, 2007, BRCA1: a novel prognostic factor in resected non-small cell lung cancer, PLoS ONE, 2, e1129, 10.1371/journal.pone.0001129 Dumontet, 2005, Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxanes chemotherapy, Bull Cancer, 92, E25 Mozzetti, 2005, Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients, Clin Cancer Res, 11, 298, 10.1158/1078-0432.298.11.1 Paradiso, 2005, Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer, Ann Oncol, 16, iv14, 10.1093/annonc/mdi902 Seve, 2005, Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel, Mol Cancer Ther, 4, 2001, 10.1158/1535-7163.MCT-05-0244 Gan, 2007, Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer, Cancer Res, 67, 9356, 10.1158/0008-5472.CAN-07-0509 Urano, 2006, Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer, Int J Oncol, 28, 375 Seve, 2007, Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10, Clin Cancer Res, 13, 994, 10.1158/1078-0432.CCR-06-1503 Pfister, 2004, American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003, J Clin Oncol, 22, 330, 10.1200/JCO.2004.09.053 Spira, 2004, Multidisciplinary management of lung cancer, N Engl J Med, 350, 379, 10.1056/NEJMra035536 Park, 2003, ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy, Clin Adv Hematol Oncol, 1, 162 Zhou, 2004, Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy, Clin Cancer Res, 10, 4939, 10.1158/1078-0432.CCR-04-0247 Booton, 2007, ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer, J Thorac Oncol, 2, 902, 10.1097/JTO.0b013e318155a637 Niedernhofer, 2007, ERCC1 and non-small-cell lung cancer, N Engl J Med, 356, 2538, 10.1056/NEJMc070742